View Post

Hope for cancer patients, as the development of immuno-oncology therapies continues to grow globally

In In The News by Barbara Jacoby

Source: GlobalData From: prnewswire.com The number of immuno-oncology (IO) therapies in clinical development and volume of clinical investigations testing these therapies for the treatment of cancer patients continue to grow, and will undoubtedly fulfill unmet needs in both hematological cancers and solid tumors over the next five to ten years. Leveraging data from GlobalData’s Pharma Intelligence platform, an Immuno-oncology Landscape update from the …

View Post

Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company

In Clinical Studies News by Barbara Jacoby

-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer- -Growing product pipeline utilizing Versamune®, a novel, versatile, multi-functional platform- -Phase 1/2 clinical data on lead product candidate PDS0101 suggests immunotherapeutic anti-cancer activity and favorable safety profile in early stage cervical cancer- -Combined company plans to initiate multiple Phase 2b/3 clinical trials of PDS0101 …

View Post

New Report Shows More than 240 Immuno-Oncology Treatments in Development for Patients with Cancer

In In The News by Barbara Jacoby

From: PR Newswire Rapid Advances in Science Fuel New Era of Medicine Aimed at Fighting Cancer A new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA)  in partnership with The American Cancer Society Cancer Action Network (ACS CAN) finds there are more than 240 immuno-oncology medicines and vaccines currently in development. Research into the role of …

View Post

Two Kidney Cancer Drugs Show Promise in Separate Studies

In In The News by Barbara Jacoby

By: Ron Winslow From: wsj.com Two drugs being tested for kidney cancer, including one from the hot field of immuno-oncology, proved superior in separate studies to a current standard treatment, setting the stage for new options for patients with an advanced stage of the disease. In one of the studies, researchers said patients taking Bristol-Myers Squibb Co. ’s Opdivo had …

View Post

Lilly leaps into new frontier of cancer drugs

In In The News by Barbara Jacoby

By: J.K. Wall From: lbj.com The hottest trend in all of pharmaceuticals right now is to use the body’s immune system to fight cancer. But the first wave of innovation in this field skipped past Eli Lilly and Co., because the company was focused in other areas. So now the Indianapolis-based drugmaker is trying to catch what it hopes will …